You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 6,790,463


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,790,463
Title: Uses of targeted oxidative therapeutic formulation in arteriosclerosis
Abstract:The use of a pharmaceutical formulation in treating coronary arteriosclerosis and a two-component pharmaceutical formulation. The pharmaceutical formulation contains peroxidic species or reaction products resulting from oxidation of an alkene, such as geraniol, by an oxygen-containing oxidizing agent, such as ozone; a penetrating solvent, such as dimithyl sulfoxide; a dye containing a chelated metal, such as hematoporphyrin; and an aromatic redox compound, such as benzoquinone.
Inventor(s): Hofmann; Robert F. (Austin, TX), Carpenter; Robert H. (Bastrop, TX)
Assignee:
Application Number:09/822,773
Patent Claims:1. An article of manufacture comprising: a first container containing a liquid phase, the liquid phase comprising: peroxidic species or reaction products resulting from oxidation of menthol or an alkene by a mixture of ozone and oxygen, wherein the alkene comprises .alpha.-terpineol, citronellol, nerol, linalool, phytol, geraniol, perillyl alcohol, geranylgeraniol or farnesol; a penetrating solvent, wherein the penetrating solvent comprises dimethylsulfoxide, sterol, lecithin, propylene glycol, or methylsulfonylmethane; and a second container containing a solid phase, the solid phase comprising: a dye containing a chelated divalent or trivalent metal, wherein the dye comprises porphyrin, rose bengal, chlorophyllin, hemin, corrins, texaphrin, methylene blue, hematoxylin, eosin, erythrosin, lactoflavin, anthracene dye, hypericin, methylcholanthrene, neutral red, or fluorescein; and an aromatic redox compound, wherein the redox compound comprises substituted or unsubstituted benzoquinone, naphthoquinone, or anthroquinone, wherein the liquid phase and the solid phase in combination comprise about 0.001% to about 30% by weight of the peroxidic species or reaction products resulting from oxidation of menthol or the alkene, from about 50% to about 99% by weight of the penetrating solvent, from about 0.1% to about 30% by weight of the dye, and from about 0.01% to about 20% by weight of the aromatic redox compound.

2. The article of manufacture of claim 1, wherein the alkene is in a liquid form, in a solution, or in a dispersion.

3. The article of manufacture of claim 1, wherein the mixture of ozone and oxygen contains singlet oxygen, oxygen in its triplet state, superoxide anion, periodate, hydroxyl radical, peroxide, or oxygen bound to a transition element.

4. The article of manufacture of claim 1, wherein the mixture of ozone and oxygen comprises predominantly ozone.

5. The article of manufacture of claim 1, wherein the penetrating solvent is a liquid, micelle membrane, emollient, plasma, or vapor.

6. The article of manufacture of claim 1, wherein the penetrating solvent is dimethylsulfoxide.

7. The article of manufacture of claim 1, wherein the dye comprises porphyrin or rose bengal.

8. The article of manufacture of claim 1, wherein the dye can be activated by an energy source.

9. The article of manufacture of claim 8, wherein the energy source comprises photon.

10. The article of manufacture of claim 8, wherein the energy source comprises laser or ionizing radiation.

11. The article of manufacture of claim 1, wherein the metal comprises iron.

12. The article of manufacture of claim 1, wherein the metal comprises copper, manganese, tin, magnesium, or strontium.

13. The article of manufacture of claim 1 further comprising an electron donor.

14. The article of manufacture claim 13, wherein the electron donor comprises ascorbic acid or a pharmaceutical salt thereof.

15. The article of manufacture of claim 13, wherein the electron donor comprises germanium sesquioxide or electrical current, wherein the electrical current is applied to the combination of the liquid phase of the first container and the solid phase of the second container after mixing.

16. A method for treating a patient with coronary arteriosclerosis comprising: administering to the patient an effective amount of a pharmaceutical formulation comprising: peroxidic species or reaction products resulting from oxidation of menthol or an alkene by an oxygen-containing oxidizing agent, wherein the alkene comprises .alpha.-terpineol, citronellol, nerol, linalool, phytol, geraniol, perillyl alcohol, geranylgeraniol or farnesol, and wherein the peroxidic species or reaction products resulting from oxidation of menthol or the alkene is from about 0.001% to about 30% by weight of the pharmaceutical formulation; a penetrating solvent, wherein the penetrating solvent comprises dimethylsulfoxide, sterol, lecithin, propylene glycol, or methylsulfonylmethane, and wherein the penetrating solvent is from about 50% to about 99% by weight of the pharmaceutical formulation; a dye containing a chelated divalent or trivalent metal, wherein the dye comprises porphyrin, rose bengal, chlorophyllin, hemin, corrins, texaphrin, methylene blue, hematoxylin, eosin, erythrosin, lactoflavin, anthracene dye, hypericin, methylcholanthrene, neutral red, or fluorescein, and wherein the dye is from about 0.1% to about 30% by weight of the pharmaceutical formulation; and an aromatic redox compound, wherein the redox compound comprises substituted or unsubstituted benzoquinone, naphthoquinone, or anthroquinone, and wherein the aromatic redox compound is from about 0.01% to about 20% by weight of the pharmaceutical formulation.

17. The method of claim 16, wherein the alkene is in a liquid form, in a solution, or in a dispersion.

18. The method of claim 16, wherein the mixture of ozone and oxygen contains singlet oxygen, oxygen in its triplet state, superoxide anion, periodate, hydroxyl radical, peroxide, or oxygen bound to a transition element.

19. The method of claim 16, wherein the mixture of ozone and oxygen comprises predominantly ozone.

20. The method of claim 16, wherein the penetrating solvent is a liquid, micelle membrane, emollient, or vapor.

21. The method of claim 16, wherein the penetrating solvent is dimethylsulfoxide.

22. The method of claim 16, wherein the dye comprises porphyrin or rose bengal.

23. The method of claim 16, wherein the metal comprises iron.

24. The method of claim 16, wherein the metal comprises copper, manganese, tin, magnesium, or strontium.

25. The method of claim 16, further comprising an electron donor.

26. The method of claim 16, wherein the electron donor comprises ascorbic acid or a pharmaceutical salt thereof.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.